Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.

In a trial investigating the effect of four courses of IV rituximab (two 1000 mg infusions every 24 weeks through 96 weeks) on time to confirmed disease worsening measured by increase in EDSS maintained for 12 weeks in a cohort of 439 PPMS patients (OLYMPUS), differences between rituximab and placebo did not reach statistical significance [ 24 ].

also in 111,027 other papers